NT-proBNP helps identify cardiovascular disease risk in women
NT-proBNP may help diagnose cardiovascular disease risk in women
HealthDay News -- N-terminal pro-B-type natriuretic peptide (NT-proBNP) may modestly improve cardiovascular disease (CVD) risk prediction in female patients, results of a study published in the Journal of the American College of Cardiology indicate.
“Although NT-proBNP has a strong relationship with incident CVD, few studies have examined whether NT-proBNP adds to risk prediction algorithms, particularly in women,” explained Brendan M. Everett, MD, MPH, of the Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues.
To evaluate the relationship between NT-proBNP and incident CVD in women, the investigators conducted a prospective case-cohort with data from 1,821 incidence cases of CVD within the Woman's Health Initiative observational study and a randomly selected reference cohort of 1,992 female patients without CVD at baseline.
Higher median levels of NT-proBNP at study entry among incident cases compared with controls (120.3 ng/L versus 100.4 ng/L; P<0.0001). After adjustment for traditional risk factors, women in the highest versus the lowest quartile of NT-proBNP were at a 53% increased risk of CVD (P<0.0001), reported the researchers.
The associations persisted after further adjustment for Reynolds Risk Score covariables and in separate analyses of cardiovascular death, myocardial infarction, and stroke. NT-proBNP improved the C-statistic, categorical net reclassification, and integrated discrimination when added to traditional risk variables. Similar results were seen for addition of NT-proBNP to the Reynolds Risk Score.
"In this multiethnic cohort of women with numerous CV events, NT-proBNP modestly improved measures of CVD risk prediction," concluded the study authors.
Disclosures: Several authors disclosed financial ties to the pharmaceutical industry.